{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:28:06Z","timestamp":1792294086114,"version":"4.4.0"},"reference-count":179,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Council Canada","award":["NRC-53613"],"award-info":[{"award-number":["NRC-53613"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Since the discovery of camelid heavy-chain antibodies in 1993, there has been tremendous excitement for these antibody domains (VHHs\/sdAbs\/nanobodies) as research tools, diagnostics, and therapeutics. Commercially, several patents were granted to pioneering research groups in Belgium and the Netherlands between 1996\u20132001. Ablynx was established in 2001 with the aim of exploring the therapeutic applications and development of nanobody drugs. Extensive efforts over two decades at Ablynx led to the first approved nanobody drug, caplacizumab (Cablivi) by the EMA and FDA (2018\u20132019) for the treatment of rare blood clotting disorders in adults with acquired thrombotic thrombocytopenic purpura (TPP). The relatively long development time between camelid sdAb discovery and their entry into the market reflects the novelty of the approach, together with intellectual property restrictions and freedom-to-operate issues. The approval of the first sdAb drug, together with the expiration of key patents, may open a new horizon for the emergence of camelid sdAbs as mainstream biotherapeutics in the years to come. It remains to be seen if nanobody-based drugs will be cheaper than traditional antibodies. In this review, I provide critical perspectives on camelid sdAbs and present the promises and challenges to their widespread adoption as diagnostic and therapeutic agents.<\/jats:p>","DOI":"10.3390\/ijms23095009","type":"journal-article","created":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T06:23:08Z","timestamp":1651386188000},"page":"5009","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments"],"prefix":"10.3390","volume":"23","author":[{"given":"Mehdi","family":"Arbabi-Ghahroudi","sequence":"first","affiliation":[{"name":"Human Health Therapeutics Research Centre, National Research Council Canada, 100 Sussex Drive, Ottawa, ON K1A 0R6, Canada"},{"name":"Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"Department of Biology, Carleton University, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"ref_1","unstructured":"Murphy, K.M., and Weaver, C. (2016). Janeway\u2019s Immunobiology: Ninth International Student Edition, Garland Science."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"MAbs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0161-5890(94)90001-9","article-title":"Anatomy of the antibody molecule","volume":"31","author":"Padlan","year":"1994","journal-title":"Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0161-5890(85)90151-8","article-title":"Immunoglobulin G: Functional sites","volume":"22","author":"Burton","year":"1985","journal-title":"Mol. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0065-3233(08)60520-3","article-title":"The anatomy and taxonomy of protein structure","volume":"34","author":"Richardson","year":"1981","journal-title":"Adv. Protein Chem."},{"key":"ref_8","first-page":"309","article-title":"The immunoglobulin fold. Structural classification, sequence patterns and common core","volume":"242","author":"Bork","year":"1994","journal-title":"J. Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.str.2004.02.011","article-title":"Structure and flexibility of individual immunoglobulin G molecules in solution","volume":"12","author":"Sandin","year":"2004","journal-title":"Structure"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/nl061598x","article-title":"Measuring the flexibility of immunoglobulin by gold nanoparticles","volume":"6","author":"Huang","year":"2006","journal-title":"Nano Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Atarhouch","year":"1993","journal-title":"Nature"},{"key":"ref_12","first-page":"561","article-title":"Camelid immunoglobulins and their importance for the new-born--a review","volume":"48","author":"Wernery","year":"2001","journal-title":"J. Vet. Med. B Infect. Dis Vet. Public Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-1759(00)00188-5","article-title":"Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama","volume":"240","author":"Stok","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"ref_14","unstructured":"Kabat, E.A. (1991). Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health."},{"key":"ref_15","unstructured":"Arbabi Ghahroudi, M. (1996). Generation and characterization of phage-displayed camel single-domain antibodies. [Ph.D. Thesis, Vrije Universiteit Brussel (VUB)]."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/protein\/7.9.1129","article-title":"Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains","volume":"7","author":"Muyldermans","year":"1994","journal-title":"Protein Eng."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0161-5890(97)00146-6","article-title":"Comparison of llama VH sequences from conventional and heavy chain antibodies","volume":"34","author":"Vu","year":"1997","journal-title":"Mol. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-5793(97)01062-4","article-title":"Selection and identification of single domain antibody fragments from camel heavy-chain antibodies","volume":"414","author":"Desmyter","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Flajnik, M.F., Deschacht, N., and Muyldermans, S. (2011). A case of convergence: Why did a simple alternative to canonical antibodies arise in sharks and camels?. PLoS Biol., 9.","DOI":"10.1371\/journal.pbio.1001120"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/19420862.2015.989032","article-title":"Structural insights and biomedical potential of IgNAR scaffolds from sharks","volume":"7","author":"Zielonka","year":"2015","journal-title":"MAbs"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Juma, S.N., Gong, X., Hu, S., Lv, Z., Shao, J., Liu, L., and Chen, G. (2021). Shark New Antigen Receptor (IgNAR): Structure, Characteristics and Potential Biomedical Applications. Cells, 10.","DOI":"10.3390\/cells10051140"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsb0996-803","article-title":"Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme","volume":"3","author":"Desmyter","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/nsb0996-752","article-title":"The crystal structure of a llama heavy chain variable domain","volume":"3","author":"Spinelli","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23645","DOI":"10.1074\/jbc.M202327200","article-title":"Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology","volume":"277","author":"Desmyter","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/jmbi.2001.4856","article-title":"Lateral recognition of a dye hapten by a llama VHH domain","volume":"311","author":"Spinelli","year":"2001","journal-title":"J. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1016\/j.molimm.2008.06.005","article-title":"Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol","volume":"45","author":"Doyle","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/bi991830w","article-title":"Camelid heavy-chain variable domains provide efficient combining sites to haptens","volume":"39","author":"Spinelli","year":"2000","journal-title":"Biochemistry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1016\/j.jmb.2018.09.002","article-title":"Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies","volume":"430","author":"Zavrtanik","year":"2018","journal-title":"J. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1016\/j.jmb.2014.08.013","article-title":"Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody-antigen complexes","volume":"426","author":"Robin","year":"2014","journal-title":"J. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3389\/fimmu.2018.02278","article-title":"Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface\/Residue Definition","volume":"9","author":"Dondelinger","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0022-2836(87)90412-8","article-title":"Canonical structures for the hypervariable regions of immunoglobulins","volume":"196","author":"Chothia","year":"1987","journal-title":"J. Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fgene.2019.00997","article-title":"The Camel Adaptive Immune Receptors Repertoire as a Singular Example of Structural and Functional Genomics","volume":"10","author":"Ciccarese","year":"2019","journal-title":"Front. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00251-018-01102-9","article-title":"Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct","volume":"71","author":"Henry","year":"2019","journal-title":"Immunogenetics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0145-305X(02)00071-X","article-title":"Emergence and evolution of functional heavy-chain antibodies in Camelidae","volume":"27","author":"Conrath","year":"2003","journal-title":"Dev. Comp. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prot.340160102","article-title":"Length distribution of CDRH3 in antibodies","volume":"16","author":"Wu","year":"1993","journal-title":"Proteins"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/emboj\/19.5.921","article-title":"Camel heavy-chain antibodies: Diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire","volume":"19","author":"Nguyen","year":"2000","journal-title":"EMBO J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.dci.2005.06.010","article-title":"Antibody repertoire development in camelids","volume":"30","author":"Saerens","year":"2006","journal-title":"Dev. Comp. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/jmbi.1997.1477","article-title":"The specific variable domain of camel heavy-chain antibodies is encoded in the germline","volume":"275","author":"Nguyen","year":"1998","journal-title":"J. Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00251-002-0433-0","article-title":"Heavy-chain antibodies in Camelidae; a case of evolutionary innovation","volume":"54","author":"Nguyen","year":"2002","journal-title":"Immunogenetics"},{"key":"ref_42","first-page":"380","article-title":"Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids","volume":"12","author":"Daley","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"De Vlieger, D., Ballegeer, M., Rossey, I., Schepens, B., and Saelens, X. (2018). Single-Domain Antibodies and Their Formatting to Combat Viral Infections. Antibodies, 8.","DOI":"10.3390\/antib8010001"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1074\/jbc.M111.242818","article-title":"Dual beneficial effect of interloop disulfide bond for single domain antibody fragments","volume":"287","author":"Govaert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.4049\/jimmunol.181.3.2001","article-title":"Tetrameric and homodimeric camelid IgGs originate from the same IgH locus","volume":"181","author":"Achour","year":"2008","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0161-5890(00)00081-X","article-title":"Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features","volume":"37","author":"Harmsen","year":"2000","journal-title":"Mol. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2015.1046648","article-title":"Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform","volume":"7","author":"Klarenbeek","year":"2015","journal-title":"MAbs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.4049\/jimmunol.0903722","article-title":"A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire","volume":"184","author":"Deschacht","year":"2010","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.vetimm.2011.12.001","article-title":"Structural analysis of effector functions related motifs, complement activation and hemagglutinating activities in Lama glama heavy chain antibodies","volume":"145","author":"Saccodossi","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/302575a0","article-title":"Somatic generation of antibody diversity","volume":"302","author":"Tonegawa","year":"1983","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1126\/science.3285470","article-title":"Assembly of a functional immunoglobulin Fv fragment in Escherichia coli","volume":"240","author":"Skerra","year":"1988","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: Filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/341544a0","article-title":"Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli","volume":"341","author":"Ward","year":"1989","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0002-9343(64)90191-3","article-title":"Heavy Chain Disease\u2014A New Disorder of Serum Gamma-Globulins: Report of the First Case","volume":"37","author":"Franklin","year":"1964","journal-title":"Am. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.2830400112","article-title":"Mu-heavy chain disease: Presentation as a benign monoclonal gammopathy","volume":"40","author":"Kyle","year":"1992","journal-title":"Am. J. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/emboj\/17.13.3512","article-title":"Potent enzyme inhibitors derived from dromedary heavy-chain antibodies","volume":"17","author":"Lauwereys","year":"1998","journal-title":"EMBO J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0014-5793(04)00304-7","article-title":"Domain swapping of a llama VHH domain builds a crystal-wide beta-sheet structure","volume":"564","author":"Spinelli","year":"2004","journal-title":"FEBS Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0969-2126(99)80049-5","article-title":"A single-domain antibody fragment in complex with RNase A: Non-canonical loop structures and nanomolar affinity using two CDR loops","volume":"7","author":"Decanniere","year":"1999","journal-title":"Structure"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"26285","DOI":"10.1074\/jbc.M102107200","article-title":"Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody","volume":"276","author":"Desmyter","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/bi0009082","article-title":"Thermal unfolding of a llama antibody fragment: A two-state reversible process","volume":"40","author":"Perez","year":"2001","journal-title":"Biochemistry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","article-title":"Single-domain antibody fragments with high conformational stability","volume":"11","author":"Dumoulin","year":"2002","journal-title":"Protein Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbagen.2003.09.006","article-title":"Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography","volume":"1624","author":"Verheesen","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"439","DOI":"10.17221\/6336-VETMED","article-title":"Single-domain antibody fragments derived from heavy-chain antibodies: A review","volume":"9","author":"Eyer","year":"2012","journal-title":"Vet. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.coph.2008.07.006","article-title":"Single-domain antibodies as building blocks for novel therapeutics","volume":"8","author":"Saerens","year":"2008","journal-title":"Curr. Opin. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","article-title":"Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity","volume":"198","author":"Wesolowski","year":"2009","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: Big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/19420862.2018.1470727","article-title":"Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs","volume":"10","author":"Detalle","year":"2018","journal-title":"MAbs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.taap.2012.07.033","article-title":"Pre-clinical studies of toxin-specific nanobodies: Evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming","volume":"264","author":"Hmila","year":"2012","journal-title":"Toxicol. Appl. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Ververken","year":"2015","journal-title":"Arthritis Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase I Study of 68Ga-HER2-Nanobody for PET\/CT Assessment of HER2 Expression in Breast Carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00253-017-8644-3","article-title":"Expression of single-domain antibody in different systems","volume":"102","author":"Liu","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/d41573-019-00104-w","article-title":"Nanobody approval gives domain antibodies a boost","volume":"18","author":"Morrison","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications of Nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal. Transduct. Target"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fimmu.2017.01589","article-title":"Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook","volume":"8","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"853008","DOI":"10.3389\/fimmu.2022.853008","article-title":"Ozoralizumab, a Humanized Anti-TNF\u03b1 NANOBODY\u00ae Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNF\u03b1 IgG","volume":"13","author":"Kyuuma","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3389\/fmicb.2020.01927","article-title":"Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms","volume":"11","author":"Kang","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2.17.1","DOI":"10.1002\/0471142735.im0217s103","article-title":"Single-domain antibodies and their utility","volume":"103","author":"Baral","year":"2013","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/protein\/gzp002","article-title":"Immunological applications of single-domain llama recombinant antibodies isolated from a naive library","volume":"22","author":"Monegal","year":"2009","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12951-015-0091-7","article-title":"Characterization and applications of Nanobodies against human procalcitonin selected from a novel naive Nanobody phage display library","volume":"13","author":"Yan","year":"2015","journal-title":"J. Nanobiotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1021\/ac0610053","article-title":"Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library","volume":"78","author":"Goldman","year":"2006","journal-title":"Anal. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e16228","DOI":"10.7554\/eLife.16228","article-title":"NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies","volume":"5","author":"Moutel","year":"2016","journal-title":"eLife"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Liu, B., and Yang, D. (2022). Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031482"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Murakami, T., Kumachi, S., Matsunaga, Y., Sato, M., Wakabayashi-Nakao, K., Masaki, H., Yonehara, R., Motohashi, M., Nemoto, N., and Tsuchiya, M. (2022). Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics. Antibodies, 11.","DOI":"10.3390\/antib11010010"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-61779-968-6_14","article-title":"Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies","volume":"911","author":"Hussack","year":"2012","journal-title":"Methods Mol. Biol"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1038\/ncomms14158","article-title":"Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state","volume":"8","author":"Rossey","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10555-005-6193-1","article-title":"Prokaryotic expression of antibodies","volume":"24","author":"Tanha","year":"2005","journal-title":"Cancer Metastasis Rev."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Jager, V., Bussow, K., Wagner, A., Weber, S., Hust, M., Frenzel, A., and Schirrmann, T. (2013). High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol., 13.","DOI":"10.1186\/1472-6750-13-52"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-61779-968-6_18","article-title":"Stable expression of chimeric heavy chain antibodies in CHO cells","volume":"911","author":"Agrawal","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0168-1656(99)00228-X","article-title":"Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae","volume":"78","author":"Frenken","year":"2000","journal-title":"J. Biotechnol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pep.2018.11.001","article-title":"An efficient constitutive expression system for Anti-CEACAM5 nanobody production in the yeast Pichia pastoris","volume":"155","author":"Chen","year":"2019","journal-title":"Protein Expr. Purif."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1073\/pnas.97.10.5399","article-title":"Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity","volume":"97","author":"Graille","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Henry, K.A., Sulea, T., van Faassen, H., Hussack, G., Purisima, E.O., MacKenzie, C.R., and Arbabi-Ghahroudi, M. (2016). A Rational Engineering Strategy for Designing Protein A-Binding Camelid Single-Domain Antibodies. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163113"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","article-title":"Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours","volume":"317","author":"Debie","year":"2020","journal-title":"J. Control Release"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1021\/acs.molpharmaceut.7b00789","article-title":"Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody","volume":"15","author":"Prantner","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/17512433.2019.1607293","article-title":"Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura","volume":"12","author":"Tersteeg","year":"2019","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/protein\/gzv039","article-title":"Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing","volume":"28","author":"Henry","year":"2015","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/anie.201507596","article-title":"Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics","volume":"55","author":"Rashidian","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1021\/acs.molpharmaceut.1c00208","article-title":"Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers with Potent ADCC","volume":"18","author":"Jo","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/antib4030141","article-title":"Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies\u00ae","volume":"4","author":"Hoefman","year":"2015","journal-title":"Antibodies"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7150\/thno.8006","article-title":"Nanobody: The \u201cmagic bullet\u201d for molecular imaging?","volume":"4","author":"Chakravarty","year":"2014","journal-title":"Theranostics"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Rossotti, M.A., Belanger, K., Henry, K.A., and Tanha, J. (2021). Immunogenicity and humanization of single-domain antibodies. FEBS J.","DOI":"10.1111\/febs.15809"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-0716-2075-5_14","article-title":"Humanization of Camelid Single-Domain Antibodies","volume":"2446","author":"Sulea","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"632687","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity Risk Profile of Nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Riazi, A., Strong, P.C., Coleman, R., Chen, W., Hirama, T., van Faassen, H., Henry, M., Logan, S.M., Szymanski, C.M., and Mackenzie, R. (2013). Pentavalent single-domain antibodies reduce Campylobacter jejuni motility and colonization in chickens. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083928"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/protein\/gzu011","article-title":"Protease-resistant single-domain antibodies inhibit Campylobacter jejuni motility","volume":"27","author":"Hussack","year":"2014","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nbt0905-1065","article-title":"Upping the ante on antibodies","volume":"23","author":"Baker","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12010-008-8266-4","article-title":"Isolation and functional characterization of single domain antibody modulators of Caspase-3 and apoptosis","volume":"157","author":"McGonigal","year":"2009","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1124\/mol.113.089516","article-title":"Regulation of beta2-adrenergic receptor function by conformationally selective single-domain intrabodies","volume":"85","author":"Staus","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3389\/fphar.2020.00686","article-title":"A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells","volume":"11","author":"Hartung","year":"2020","journal-title":"Front. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.114.094821","article-title":"Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action","volume":"87","author":"Bradley","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-pharmtox-010716-104710","article-title":"Nanobodies to Study G Protein-Coupled Receptor Structure and Function","volume":"57","author":"Manglik","year":"2017","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1074\/jbc.M307341200","article-title":"Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm","volume":"279","author":"Stijlemans","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Soleimanizadeh, A., Dinter, H., and Schindowski, K. (2021). Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration. Antibodies, 10.","DOI":"10.3390\/antib10040047"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1096\/fj.01-0343fje","article-title":"Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium","volume":"16","author":"Muruganandam","year":"2002","journal-title":"FASEB J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1471-4159.2005.03463.x","article-title":"The blood-brain barrier transmigrating single domain antibody: Mechanisms of transport and antigenic epitopes in human brain endothelial cells","volume":"95","author":"Abulrob","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1096\/fj.201500078","article-title":"Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1","volume":"30","author":"Webster","year":"2016","journal-title":"FASEB J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1096\/fj.11-201384","article-title":"Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: Application to brain imaging","volume":"26","author":"Li","year":"2012","journal-title":"FASEB J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/j.1476-5381.2011.01723.x","article-title":"Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier","volume":"165","author":"Caljon","year":"2012","journal-title":"Br. J. Pharm."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Pothin, E., Lesuisse, D., and Lafaye, P. (2020). Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12100937"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1096\/fj.14-253369","article-title":"A novel platform for engineering blood-brain barrier-crossing bispecific biologics","volume":"28","author":"Farrington","year":"2014","journal-title":"FASEB J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1021\/acs.bioconjchem.0c00003","article-title":"Molecularly Engineered Nanobodies for Tunable Pharmacokinetics and Drug Delivery","volume":"31","author":"Glassman","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kouhi, A., Pachipulusu, V., Kapenstein, T., Hu, P., Epstein, A.L., and Khawli, L.A. (2021). Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126442"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Soetens, E., Ballegeer, M., and Saelens, X. (2020). An Inside Job: Applications of Intracellular Single Domain Antibodies. Biomolecules, 10.","DOI":"10.3390\/biom10121663"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nsmb.1727","article-title":"Modulation of protein properties in living cells using nanobodies","volume":"17","author":"Kirchhofer","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1074\/jbc.R115.679811","article-title":"Nanobodies as Probes for Protein Dynamics In Vitro and in Cells","volume":"291","author":"Dmitriev","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1083\/jcb.201409074","article-title":"Nanobodies and recombinant binders in cell biology","volume":"209","author":"Helma","year":"2015","journal-title":"J. Cell Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fimmu.2017.00771","article-title":"Nanobody Technology: A Versatile Toolkit for Microscopic Imaging, Protein-Protein Interaction Analysis, and Protein Function Exploration","volume":"8","author":"Beghein","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Weiss, R.A., and Verrips, C.T. (2019). Nanobodies that Neutralize HIV. Vaccines, 7.","DOI":"10.3390\/vaccines7030077"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"105265","DOI":"10.1016\/j.antiviral.2022.105265","article-title":"A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy","volume":"199","author":"Wang","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3389\/fmicb.2019.02665","article-title":"A Novel Single Domain Antibody Targeting FliC Flagellin of Salmonella enterica for Effective Inhibition of Host Cell Invasion","volume":"10","author":"Huen","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tibtech.2003.08.007","article-title":"Domain antibodies: Proteins for therapy","volume":"21","author":"Holt","year":"2003","journal-title":"Trends Biotechnol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/aps.2010.120","article-title":"Research and development of next generation of antibody-based therapeutics","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharm. Sin."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-12-1012","article-title":"Single-domain antibody-based and linker-free bispecific antibodies targeting FcgammaRIII induce potent antitumor activity without recruiting regulatory T cells","volume":"12","author":"Rozan","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"40098","DOI":"10.1038\/srep40098","article-title":"Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence","volume":"7","author":"Mazor","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: First global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"ref_146","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/15384047.2016.1139266","article-title":"A novel bispecific antibody, BiSS, with potent anti-cancer activities","volume":"17","author":"Dong","year":"2016","journal-title":"Cancer Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/15384047.2016.1235659","article-title":"Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity","volume":"17","author":"Li","year":"2016","journal-title":"Cancer Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/15384047.2019.1665953","article-title":"Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies","volume":"21","author":"Zhao","year":"2020","journal-title":"Cancer Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"838082","DOI":"10.3389\/fimmu.2021.838082","article-title":"Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1038\/s41467-020-19204-y","article-title":"Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2","volume":"11","author":"Custodio","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1038\/s41467-020-18174-5","article-title":"An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41586-021-03676-z","article-title":"Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants","volume":"595","author":"Xu","year":"2021","journal-title":"Nature"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e54199","DOI":"10.15252\/embr.202154199","article-title":"Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance","volume":"23","author":"Walter","year":"2022","journal-title":"EMBO Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e107985","DOI":"10.15252\/embj.2021107985","article-title":"Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies","volume":"40","author":"Guttler","year":"2021","journal-title":"EMBO J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1096\/fj.201903231R","article-title":"Serum albumin-binding VH Hs with variable pH sensitivities enable tailored half-life extension of biologics","volume":"34","author":"Ryan","year":"2020","journal-title":"FASEB J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1021\/ac058044j","article-title":"Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment","volume":"78","author":"Ladenson","year":"2006","journal-title":"Anal. Chem"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1007\/s00216-016-9585-x","article-title":"VHH antibodies: Emerging reagents for the analysis of environmental chemicals","volume":"408","author":"Bever","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2014.05.001","article-title":"Potential candidate camelid antibodies for the treatment of protein-misfolding diseases","volume":"272","author":"David","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12967-014-0343-6","article-title":"Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications","volume":"12","author":"Yan","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"29562","DOI":"10.1074\/jbc.M113.498436","article-title":"Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo","volume":"288","author":"Maussang","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"McCoy, L.E., Rutten, L., Frampton, D., Anderson, I., Granger, L., Bashford-Rogers, R., Dekkers, G., Strokappe, N.M., Seaman, M.S., and Koh, W. (2014). Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004552"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.4049\/jimmunol.1500888","article-title":"Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor","volume":"196","author":"Peyrassol","year":"2016","journal-title":"J. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-0716-2075-5_3","article-title":"Llama DNA Immunization and Isolation of Functional Single-Domain Antibody Binders","volume":"2446","author":"Trempe","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2567.2003.01633.x","article-title":"Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells","volume":"109","author":"Nguyen","year":"2003","journal-title":"Immunology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.4049\/jimmunol.175.6.3769","article-title":"Expression of a dromedary heavy chain-only antibody and B cell development in the mouse","volume":"175","author":"Zou","year":"2005","journal-title":"J. Immunol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.1073\/pnas.0601108103","article-title":"Generation of heavy-chain-only antibodies in mice","volume":"103","author":"Janssens","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(82)92619-8","article-title":"Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia","volume":"1","author":"Prentice","year":"1982","journal-title":"Lancet"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"MAbs"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nbt1126","article-title":"Selecting and screening recombinant antibody libraries","volume":"23","author":"Hoogenboom","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nbt0409-331","article-title":"Development trends for therapeutic antibody fragments","volume":"27","author":"Nelson","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.iy.12.040194.002245","article-title":"Making antibodies by phage display technology","volume":"12","author":"Winter","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"ref_175","first-page":"899","article-title":"Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen","volume":"12","author":"Jespers","year":"1994","journal-title":"Biotechnology"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"I70","DOI":"10.1136\/ard.58.2008.i70","article-title":"Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7","volume":"58","author":"Kempeni","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","article-title":"Nanobody-based products as research and diagnostic tools","volume":"32","author":"Muyldermans","year":"2014","journal-title":"Trends Biotechnol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.2147\/IJN.S107194","article-title":"Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications","volume":"11","author":"Wang","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/9\/5009\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:04Z","timestamp":1760137504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/9\/5009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":179,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23095009"],"URL":"https:\/\/doi.org\/10.3390\/ijms23095009","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]}}}